Michael Goettler, Viatris CEO
February 28, 2022 01:57 PM EST
Pharma
Law

Vi­a­tris agrees to pay $264M to set­tle EpiPen class ac­tion case

Paul Schloesser

Associate Editor

Just as Bio­con signs off on a $3.3 bil­lion buy­out of their shared biosim­i­lars busi­ness, Vi­a­tris’s pend­ing law­suit for its con­tro­ver­sial EpiPen might be no …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times